Emerging Roles and Potential Applications of Non-Coding RNAs in Glioblastoma

Autor(es)

DeOcesano-Pereira, Carlos ^[1] ; Machado, Raquel A. C. ^[2] ; Chudzinski-Tavassi, Ana Marisa ^[1] ; Sogayar, Mari Cleide ^{[3, 4]}

Afiliação do(s) autor(es)

^[1] Butantan Inst, Ctr Excellence New Target Discovery CENTD, 1500 Vital Brazil Ave, BR-05503900 Sao Paulo, SP - Brazil

^[2] Univ Luxembourg, Dept Life Sci & Med, Campus Belval, Ave Hauts Fourneaux, L-4362 Esch Sur Alzette - Luxembourg

^[3] Univ Sao Paulo, Chem Inst, Biochem Dept, BR-05508000 Sao Paulo - Brazil

^[4] Univ Sao Paulo, Sch Med, Cell & Mol Therapy Ctr NUCEL, BR-05360130 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 21, n. 7 APR 2020.
• Citações Web of Science: 0

Resumo

Non-coding RNAs (ncRNAs) comprise a diversity of RNA species, which do not have the potential to encode proteins. Non-coding RNAs include two classes of RNAs, namely: short regulatory ncRNAs and long non-coding RNAs (lncRNAs). The short regulatory RNAs, containing up to 200 nucleotides, include small RNAs, such as microRNAs (miRNA), short interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs). The lncRNAs include long antisense RNAs and long intergenic RNAs (lincRNAs). Non-coding RNAs have been implicated as master regulators of several biological processes, their expression being strictly regulated under physiological conditions. In recent years, particularly in the last decade, substantial effort has been made to investigate the function of ncRNAs in several human diseases, including cancer. Glioblastoma is the most common and aggressive type of brain cancer in adults, with deregulated expression of small and long ncRNAs having been implicated in onset, progression, invasiveness, and recurrence of this tumor. The aim of this review is to guide the reader through important aspects of miRNA and lncRNA biology, focusing on the molecular mechanism associated with the progression of this highly malignant cancer type. (AU)

• Processo FAPESP: 15/50040-4 - Rational approach for searching molecular targets involved in inflammatory events and cell survival
• Beneficiário: Ana Marisa Chudzinski-Tavassi
• Modalidade de apoio: Auxílio à Pesquisa - Programa Centros de Pesquisa em Engenharia
• Processo FAPESP: 16/05311-2 - Medicina regenerativa visando à terapia de doenças crônico-degenerativas (câncer e diabetes)
• Beneficiário: Mari Cleide Sogayar
• Modalidade de apoio: Auxílio à Pesquisa - Temático